Oncternal Therapeutics, Inc.
NASDAQ:ONCT
Overview | Financials
Company Name | Oncternal Therapeutics, Inc. |
Symbol | ONCT |
Currency | USD |
Price | 1.62 |
Market Cap | 4,794,633 |
Dividend Yield | 0% |
52-week-range | 1.05 - 13.2 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. James B. Breitmeyer M.D., Ph.D. |
Website | https://www.oncternal.com |
An error occurred while fetching data.
About Oncternal Therapeutics, Inc.
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD